Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
EWSR1 encodes a multifunctional protein that is involved in various cellular processes, including gene expression, cell signaling, and RNA processing and transport. Additionally we are shipping EWSR1 Proteins (4) and EWSR1 Kits (3) and many more products for this protein.
Showing 10 out of 153 products:
Human Polyclonal EWSR1 Primary Antibody for ICC, IF - ABIN152318
Davis, Kim, Ozsolak, Widlund, Rozenblatt-Rosen, Granter, Du, Fletcher, Denny, Lessnick, Linehan, Kung, Fisher: Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. in Cancer cell 2006
Human Polyclonal EWSR1 Primary Antibody for IP, WB - ABIN152319
Sohn, Park, Kang, Wu: Accumulation of pre-let-7g and downregulation of mature let-7g with the depletion of EWS. in Biochemical and biophysical research communications 2012
Human Polyclonal EWSR1 Primary Antibody for IHC (p), IHC - ABIN449908
Toretsky, Erkizan, Levenson, Abaan, Parvin, Cripe, Rice, Lee, Uren: Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. in Cancer research 2006
Gnai1 (show GNAI1 Antibodies) function is impaired in the spinal cord of Ews/Ewsr1 KO mice
EWS is normally O-GlcNAc glycosylated in the brain.
glycosylation of EWS protein
EWSR1 is involved in the post-transcriptional regulation of Uvrag (show UVRAG Antibodies) via a miRNA-dependent pathway, resulting in the deregulation of autophagy inhibition.
EWS is essential during the early steps of white adipocyte differentiation, at least in part through its regulation of BMP2 (show BMP2 Antibodies) and BMP4 (show BMP4 Antibodies) expression.
EWS has a role in mitochondrial and cellular energy homeostasis that involves controlling PGC-1alpha (show PPARGC1A Antibodies) protein stability
both Etv1 (show ETV1 Antibodies) and Ewsr1 were necessary for Fgf10 (show FGF10 Antibodies) expression and elongation of the limb bud.
EWS is involved in post-transcriptional regulation of Col4a1 (show COL4A1 Antibodies) and CTGF (show CTGF Antibodies) via a Drosha (show DROSHA Antibodies)-miRNA-dependent pathway.
These results demonstrate that EWS is essential for early brown fat lineage determination.
Forced expression of EWS/ATF1 (show AFT1 Antibodies) resulted in the development of EWS/ATF1 (show AFT1 Antibodies)-dependent sarcomas. Lineage-tracing experiments indicated that neural crest-derived cells were subject to EWS/ATF1 (show AFT1 Antibodies)-driven transformation.
Mutation of the EWS gene modulates Sox9 (show SOX9 Antibodies) gene expression essential for chondrocyte differentiation.
Ewsr1 maintains mitotic integrity and proneural cell survival in early zebrafish development
Interaction between EWSR1/FLI1 (show FLI1 Antibodies) and EWSR1 in Ewing sarcoma may induce mitotic defects leading to genomic instability and subsequent malignant transformation.
Recent advances in biologic and genomic understanding of these two cancers has expanded the potential for therapeutic advancement and prevention. In Ewing sarcoma, directed focus on inhibition of EWSR1-FLI1 (show FLI1 Antibodies) and its effectors has produced promising results.
data suggest EWS/FLI (show FLII Antibodies) binds to "promoter-like" and "enhancer-like" microsatellites to mediate activation and repression of target genes through different regulatory mechanisms
four oncogenic ETS (show ETS1 Antibodies) (ERG (show ERG Antibodies), ETV1 (show ETV1 Antibodies), ETV4 (show ETV4 Antibodies), and ETV5 (show ETV5 Antibodies)), and no other ETS (show ETS1 Antibodies), interact with the Ewing's sarcoma breakpoint protein, EWS.
As spontaneous fluctuations in EWS-FLI1 (show FLI1 Antibodies) levels of Ewing sarcoma cells in vitro and in vivo, associated with a switch between a proliferative, non-migratory EWS-FLI1 (show FLI1 Antibodies)-high and a non-proliferative highly migratory EWS-FLI1 (show FLI1 Antibodies)-low state, were recently described, our data provide a mechanistic basis for the underlying EWS-FLI1 (show FLI1 Antibodies)-dependent reversible cytoskeletal reprogramming of Ewing sarcoma cells.
Fusion of short fragments of EWSR1 to FLI1 (show FLI1 Antibodies) is sufficient to recapitulate BAF (show BANF1 Antibodies) complex retargeting and EWS-FLI1 (show FLI1 Antibodies) activities; studies thus demonstrate that the physical properties of prion (show PRNP Antibodies)-like domains can retarget critical chromatin regulatory complexes to establish and maintain oncogenic gene expression programs.
Case Reports: maxillary sinus clear cell carcinomas with EWSR1-ATF1 (show AFT1 Antibodies) gene fusion.
Results expand the spectrum of tumor types harboring EWSR1/FUS (show FUS Antibodies)-ATF1 (show AFT1 Antibodies) gene fusions to include a subgroup of conventional epithelioid malignant mesothelioma.
papillary thyroid carcinomas with EWSR1 rearrangement disclosed a lower percentage of nuclei with EWSR1 polysomy than those without EWSR1 rearrangement
The net result of combined lurbinectedin and irinotecan treatment was a complete reversal of EWS-FLI1 (show FLI1 Antibodies) activity and elimination of established tumors in 30% to 70% of mice after only 11 days of therapy. Our results illustrate the preclinical safety and efficacy of a disease-specific therapy targeting the central oncogenic driver in Ewing sarcoma.
Aggregation of FET proteins FUS (show FUS Antibodies), EWSR1, and TAF15 (show TAF15 Antibodies) mediate a pathological change in amyotrophic lateral sclerosis. (Review)
This gene encodes a multifunctional protein that is involved in various cellular processes, including gene expression, cell signaling, and RNA processing and transport. The protein includes an N-terminal transcriptional activation domain and a C-terminal RNA-binding domain. Chromosomal translocations between this gene and various genes encoding transcription factors result in the production of chimeric proteins that are involved in tumorigenesis. These chimeric proteins usually consist of the N-terminal transcriptional activation domain of this protein fused to the C-terminal DNA-binding domain of the transcription factor protein. Mutations in this gene, specifically a t(11\;22)(q24\;q12) translocation, are known to cause Ewing sarcoma as well as neuroectodermal and various other tumors. Alternative splicing of this gene results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 1 and 14.
RNA-binding protein EWS
, Ewing sarcoma RNA-binding protein
, Ewing sarcoma breakpoint region 1
, Ewing sarcoma homolog
, Ewings sarcoma EWS-Fli1 (type 1) oncogene